The Retinopathy of Prematurity Market Share is contested primarily across two distinct competitive axes: the pharmaceutical segment (anti-VEGF drugs) and the medical device segment (laser systems and imaging equipment). In the pharmaceutical space, a few global biopharma giants dominate the market share, leveraging their existing, widely-used anti-VEGF agents for off-label use in ROP, or...